Table 4.
Sensitivity analyses of the association between high-sensitivity C-reactive protein (hsCRP) and incidence of conduction disorders
| Cases/Total | Incidence/1000-person years | Model 1 HR (95% CI) |
Model 2 HR (95%CI) |
Model 3 HR (95%CI) |
Model 4 HR (95%CI) |
|
|---|---|---|---|---|---|---|
| Regrouping of hsCRP | ||||||
| Any Cardiac conduction disorder | ||||||
| hsCRP < 1 mg/L | 1800/48180 | 3.48 (3.33–3.65) | Reference | Reference | Reference | Reference |
| hsCRP ≥ 1 mg/L | 1814/38054 | 4.58 (4.38–4.81) | 1.26 (1.18–1.34) | 1.22 (1.14–1.30) | 1.21 (1.13–1.29) | 1.19 (1.11–1.27) |
| Any Atrioventricular Block | ||||||
| hsCRP < 1 mg/L | 511/48180 | 0.99 (0.91–1.08) | Reference | Reference | Reference | Reference |
| hsCRP ≥ 1 mg/L | 610/38054 | 1.54 (1.43–1.67) | 1.49 (1.32–1.67) | 1.38 (1.22–1.56) | 1.37 (1.21–1.54) | 1.33 (1.17–1.50) |
| Any Bundle- branch Block | ||||||
| hsCRP < 1 mg/L | 1307/48180 | 2.53 (2.39–2.67) | Reference | Reference | Reference | Reference |
| hsCRP ≥ 1 mg/L | 1229/38054 | 3.11 (2.94–3.29) | 1.17 (1.08–1.27) | 1.15 (1.06–1.25) | 1.14 (1.05–1.24) | 1.13 (1.05–1.23) |
| Any Left Bundle- branch Block | ||||||
| hsCRP < 1 mg/L | 523/48180 | 1.01 (0.93–1.10) | Reference | Reference | Reference | Reference |
| hsCRP ≥ 1 mg/L | 462/38054 | 1.17 (1.07–1.28) | 1.08 (0.95–1.22) | 1.03 (0.91–1.17) | 1.03 (0.90–1.17) | 1.02 (0.90–1.17) |
| Right Bundle- branch Block | ||||||
| hsCRP < 1 mg/L | 877/48180 | 1.69 (1.59–1.81) | Reference | Reference | Reference | Reference |
| hsCRP ≥ 1 mg/L | 863/38054 | 2.18 (2.04–2.33) | 1.24 (1.12–1.36) | 1.24 (1.12–1.36) | 1.22 (1.11–1.34) | 1.21 (1.09–1.33) |
| Excluding hsCRP > 10 mg/L at baseline (N = 3342) | ||||||
| Any Cardiac conduction disorder | ||||||
| hsCRP ≤ 3 mg/L | 2674/70002 | 3.59 (3.46–3.74) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 758/12890 | 5.66 (5.27–6.08) | 1.44 (1.33–1.57) | 1.44 (1.33–1.56) | 1.43 (1.32–1.55) | 1.41 (1.30–1.53) |
| log (hsCRP)/SD | 3432/82892 | 3.91 (3.78–4.04) | 1.18 (1.14–1.23) | 1.16 (1.12–1.21) | 1.15 (1.11–1.20) | 1.14 (1.10–1.19) |
| Any Atrioventricular Block | ||||||
| hsCRP ≤ 3 mg/L | 781/70002 | 1.05 (0.98–1.13) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 274/12890 | 2.05 (1.82–2.30) | 1.75 (1.52–2.02) | 1.71 (1.49–1.97) | 1.70 (1.47–1.96) | 1.66 (1.44–1.92) |
| log (hsCRP)/SD | 1055/82892 | 1.20 (1.13–1.28) | 1.32 (1.23–1.41) | 1.27 (1.18–1.36) | 1.26 (1.17–1.36) | 1.25 (1.16–1.34) |
| Any Bundle- branch Block | ||||||
| hsCRP ≤ 3 mg/L | 1921/70002 | 2.58 (2.47–2.70) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 495/12890 | 3.69 (3.38–4.04) | 1.32 (1.19–1.46) | 1.33 (1.20–1.47) | 1.32 (1.19–1.46) | 1.31 (1.18–1.45) |
| log (hsCRP)/SD | 2416/82892 | 2.75 (2.64–2.86) | 1.13 (1.08–1.18) | 1.12 (1.07–1.17) | 1.11 (1.06–1.16) | 1.10 (1.05–1.15) |
| Any Left Bundle- branch Block | ||||||
| hsCRP ≤ 3 mg/L | 744/70002 | 1.00 (0.93–1.07) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 194/12890 | 1.45 (1.26–1.67) | 1.32 (1.12–1.55) | 1.28 (1.09–1.51) | 1.28 (1.09–1.51) | 1.27 (1.08–1.50) |
| log (hsCRP)/SD | 938/82892 | 1.07 (1.00–1.14) | 1.08 (1.00–1.16) | 1.05 (0.97–1.12) | 1.04 (0.97–1.12) | 1.04 (0.97–1.12) |
| Right Bundle- branch Block | ||||||
| hsCRP ≤ 3 mg/L | 1320/70002 | 1.77 (1.68–1.87) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 339/12890 | 2.53 (2.27–2.81) | 1.32 (1.17–1.48) | 1.36 (1.20–1.54) | 1.34 (1.19–1.52) | 1.33 (1.17–1.50) |
| log (hsCRP)/SD | 1659/82892 | 1.89 (1.80–1.98) | 1.16 (1.10–1.23) | 1.16 (1.10–1.23) | 1.15 (1.09–1.22) | 1.14 (1.08–1.21) |
| Excluding Myocardial Infarction at baseline (N = 965) | ||||||
| Any Cardiac conduction disorder | ||||||
| hsCRP ≤ 3 mg/L | 2629/69270 | 3.56 (3.43–3.70) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 919/15999 | 5.54 (5.19–5.19) | 1.43 (1.32–1.54) | 1.43 (1.32–1.54) | 1.42 (1.31–1.53) | 1.39 (1.29–1.51) |
| log (hsCRP)/SD | 3548/85269 | 3.93 (3.80–4.06) | 1.17 (1.13–1.21) | 1.15 (1.11–1.19) | 1.15 (1.11–1.18) | 1.14 (1.10–1.18) |
| Any Atrioventricular Block | ||||||
| hsCRP ≤ 3 mg/L | 770/69270 | 1.04 (0.97–1.12) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 332/15999 | 2.00 (1.79–2.23) | 1.73 (1.52–1.97) | 1.69 (1.48–1.93) | 1.68 (1.47–1.92) | 1.63 (1.43–1.87) |
| log (hsCRP)/SD | 1102/85269 | 1.22 (1.15–1.29) | 1.28 (1.21–1.37) | 1.25 (1.17–1.33) | 1.24 (1.17–1.32) | 1.22 (1.15–1.30) |
| Any Bundle- branch Block | ||||||
| hsCRP ≤ 3 mg/L | 1887/69270 | 2.56 (2.45–2.68) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 601/15999 | 3.62 (3.34–3.92) | 1.31 (1.18–1.43) | 1.32 (1.20–1.45) | 1.31 (1.19–1.44) | 1.30 (1.18–1.43) |
| log (hsCRP)/SD | 2488/85269 | 2.75 (2.65–2.86) | 1.12 (1.01–1.17) | 1.11 (1.07–1.16) | 1.11 (1.06–1.15) | 1.10 (1.06–1.15) |
| Any Left Bundle- branch Block | ||||||
| hsCRP ≤ 3 mg/L | 734/69270 | 0.99 (0.93–1.07) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 231/15999 | 1.39 (1.23–1.58) | 1.27 (1.09–1.48) | 1.23 (1.05–1.43) | 1.23 (1.06–1.44) | 1.22 (1.05–1.43) |
| log (hsCRP)/SD | 965/85269 | 1.97 (1.00–1.14) | 1.07 (1.00–1.14) | 1.04 (0.97–1.11) | 1.04 (0.97–1.11) | 1.03 (0.96–1.11) |
| Right Bundle- branch Block | ||||||
| hsCRP ≤ 3 mg/L | 1295/69270 | 1.75 (1.66–1.86) | Reference | Reference | Reference | Reference |
| hsCRP > 3 mg/L | 414/15999 | 2.49 (2.27–2.75) | 1.31 (1.17–1.46) | 1.36 (1.21–1.52) | 1.34 (1.19–1.51) | 1.33 (1.18–1.49) |
| log (hsCRP)/SD | 1709/85269 | 1.89 (1.81–1.98) | 1.15 (1.09–1.21) | 1.15 (1.10–1.21) | 1.15 (1.09–1.20) | 1.14 (1.01–1.20) |
Model 1: Corrected for age and gender
Model 2: Corrected for baseline body mass index, physical activity, smoking, alcohol consumption, cholesterol, uric acid, estimated glomerular filtration rate, hypertension, diabetes mellitus, and myocardial infarction based on model 1
Model 3: Corrected for new-onset hypertension, diabetes mellitus, and myocardial infarction during the follow-up based on model 2
Model 4: Corrected for those taking antihypertensive, lipid-lowering, and glucose-lowering drugs at baseline or during the follow-up based on model 3
HR, hazard ratio; Log (hsCRP)/SD, log-transformed for each standard deviation increase in hsCRP; CI, confidence interval